Adjuvant denosumab in early breast-cancer
- Autori: Fusco V.; Campisi G.; Bedogni A.
- Anno di pubblicazione: 2020
- Tipologia: Lettera
- OA Link: http://hdl.handle.net/10447/408720
Abstract
We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).